Multitarget Drugs: an Epigenetic Epiphany

被引:59
作者
Ganesan, A. [1 ]
机构
[1] Univ E Anglia, Sch Pharm, Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England
关键词
cancer; dual inhibitors; epigenetics; histone deacetylases; multitarget drugs; INOSINE MONOPHOSPHATE DEHYDROGENASE; HISTONE DEACETYLASE INHIBITORS; SMALL-MOLECULE INHIBITORS; BIOLOGICAL EVALUATION; DUAL INHIBITORS; HYDROXAMIC ACID; SELECTIVE INHIBITORS; POTENT INHIBITORS; ROMIDEPSIN FK228; TOPOISOMERASE-II;
D O I
10.1002/cmdc.201500394
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Epigenetics refers to changes in a biological phenotype that are not due to an underlying change in genotype. In eukaryotes, epigenetics involves a set of chemical modifications of the DNA and the histone proteins in nucleosomes. These dynamic changes are carried out by enzymes and modulate protein-protein and protein-nucleic acid interactions to determine whether specific genes are expressed or silenced. Both the epigenetic enzymes and recognition domains are currently important drug discovery targets, particularly for the treatment of cancer. This review summarizes the progress of epigenetic targets that have reached a clinical stage: DNA methyltransferases, histone deacetylases, lysine methyltransferases, lysine demethylases, and bromodomains; this is followed by a comprehensive survey of multitarget drugs that have included an epigenetic target as one of their mechanisms of action.
引用
收藏
页码:1227 / 1241
页数:15
相关论文
共 87 条
[1]   Epigenetic Multiple Modulators [J].
Alvarez, Rosana ;
Altucci, Lucia ;
Gronemeyer, Hinrich ;
de Lera, Angel R. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (22) :2749-2787
[2]   The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes [J].
Atkinson, Stephen J. ;
Soden, Peter E. ;
Angell, Davina C. ;
Bantscheff, Marcus ;
Chung, Chun-wa ;
Giblin, Kathryn A. ;
Smithers, Nicholas ;
Furze, Rebecca C. ;
Gordon, Laurie ;
Drewes, Gerard ;
Rioja, Inmaculada ;
Witherington, Jason ;
Parr, Nigel J. ;
Prinjha, Rab K. .
MEDCHEMCOMM, 2014, 5 (03) :342-351
[3]   Chemical con artists foil drug discovery [J].
Baell, Jonathan ;
Walters, Michael A. .
NATURE, 2014, 513 (7519) :481-483
[4]   Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets [J].
Baud, Matthias G. J. ;
Leiser, Thomas ;
Haus, Patricia ;
Samlal, Sharon ;
Wong, Ai Ching ;
Wood, Robert J. ;
Petrucci, Vanessa ;
Gunaratnam, Mekala ;
Hughes, Siobhan M. ;
Buluwela, Lakjaya ;
Turlais, Fabrice ;
Neidle, Stephen ;
Meyer-Almes, Franz-Josef ;
White, Andrew J. P. ;
Fuchter, Matthew J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (04) :1731-1750
[5]   Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases [J].
Beckers, Thomas ;
Mahboobi, Siavosh ;
Sellmer, Andreas ;
Winkler, Matthias ;
Eichhorn, Emerich ;
Pongratz, Herwig ;
Maier, Thomas ;
Ciossek, Thomas ;
Baer, Thomas ;
Kelter, Gerhard ;
Fiebig, Heinz-Herbert ;
Schmidt, Mathias .
MEDCHEMCOMM, 2012, 3 (07) :829-835
[6]   Mycophenolic acid: A one hundred year odyssey from antibiotic to immunosuppressant [J].
Bentley, R .
CHEMICAL REVIEWS, 2000, 100 (10) :3801-3825
[7]  
Blagodatski A., 2014, MOL CELL THER, V2, P28
[8]   Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor [J].
Borretto, Emily ;
Lazzarato, Loretta ;
Spallotta, Francesco ;
Cencioni, Chiara ;
D'Alessandra, Yuri ;
Gaetano, Carlo ;
Fruttero, Roberta ;
Gasco, Alberto .
ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (10) :994-999
[9]   Post-Translational Modifications of Histones That Influence Nucleosome Dynamics [J].
Bowman, Gregory D. ;
Poirier, Michael G. .
CHEMICAL REVIEWS, 2015, 115 (06) :2274-2295
[10]   Small Molecule Inhibitors of Bromodomain-Acetyl-lysine Interactions [J].
Brand, Michael ;
Measures, Angelina M. ;
Wilson, Brian G. ;
Cortopassi, Wilian A. ;
Alexander, Rikki ;
Hoess, Matthias ;
Hewings, David S. ;
Rooney, Timothy P. C. ;
Paton, Robert S. ;
Conway, Stuart J. .
ACS CHEMICAL BIOLOGY, 2015, 10 (01) :22-39